Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6489-6494

  Martínez, Alfredo ^a   Zudaire, Enrique ^a   Portal Núñez, Sergio ^a   Guédez, Liliana ^a   Libutti, Steven K ^a   Stetler Stevenson, William G ^a   Cuttitta, Frank ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; PEPTIDE FRAGMENT; PROADRENOMEDULLIN; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; CALCIUM; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHICK EMBRYO; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT; ANIMAL; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADRENOMEDULLIN; ANIMALS; CALCIUM; CELL DIVISION; CELL LINE, TUMOR; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644266912     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0103     Document Type: Article

References (34)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
2. Distler J, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149-61.
3. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
4. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
5. Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000;50:63-70.
6. Scappaticci FA. The therapeutic potential of novel antiangiogenic therapies. Expert Opin Investig Drugs 2003;12:923-32.
7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
8. López J, Martínez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol 2002;221:1-92.
9. Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees MC. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998;16:409-15.
10. Martínez A, Vos M, Guédez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst (Bethesda) 2002;94:1226-37.
11. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21:2815-21.
12. Ishikawa T, Chen J, Wang J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003;22:1238-42.
13. Cuttitta F, Pío R, Garayoa M, et al. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 2002;57:110-9.
14. Isaacs JS, Jung Y, Mimnaugh EG, Martínez A, Cuttitta F, Neckers LM. Hsp90 regulates a VHL-independent HIF-1α degradative pathway. J Biol Chem 2002;277:29936-44.
15. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
16. Guédez L, Rivera AM, Salloum R, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003;162:1431-9.
17. Lau KL, Kong SK, Ko WH, Kwan HY, Huang Y, Yao X. cGMP stimulates endoplasmic reticulum Ca(2+)-ATPase in vascular endothelial cells. Life Sci 2003;73:2019-28.
18. Macpherson GR, Ng SS, Forbes SL, et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther 2003;2:845-54.
19. Martínez A, Saldise L, Ramírez MJ, et al. Adrenomedullin expression and function in the rat carotid body. J Endocrinol 2003;176:95-102.
20. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002;160:1279-92.
21. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-9.
22. Katoh F, Kitamura K, Niina H, et al. Proadrenomedullin N-terminal 20 peptide (PAMP), an endogenous anticholinergic peptide: its exocytotic secretion and inhibition of catecholamine secretion in adrenal medulla. J Neurochem 1995;64:459-61.
23. Belloni AS, Rossi GP, Andreis PG, et al. Proadrenomedullin N-terminal 20 peptide (PAMP), acting through PAMP(12-20)-sensitive receptors, inhibits Ca2+-dependent, agonist-stimulated secretion of human adrenal glands. Hypertension 1999;33:1185-9.
24. Yahata Y, Shirakata Y, Tokumaru S, et al. Nuclear translocation of phosphorylated STAT3 is essential for VEGF-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 2003;278:40026-31.
25. Chlenski A, Liu S, Cohn SL. The regulation of angiogenesis in neuroblastoma. Cancer Lett 2003;197:47-52.
26. Montuenga LM, Martínez A, Miller MJ, Unsworth EJ, Cuttitta F. Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action. Endocrinology 1997;138:440-51.
27. Martínez A, Hodge DL, Garayoa M, Young HA, Cuttitta F. Alternative splicing of the proadrenomedullin gene results in differential expression of gene products. J Mol Endocrinol 2001;27:31-41.
28. Nagatomo Y, Kitamura K, Kangawa K, Fujimoto Y, Eto T. Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Biochem Biophys Res Commun 1996;223:539-43.
29. Washimine H, Kitamura K, Ichiki Y, et al. Immunoreactive proadrenomedullin N-terminal 20 peptide in human tissue, plasma and urine. Biochem Biophys Res Commun 1994;202:1081-7.
30. Miller MJ, Martínez A, Unsworth EJ, et al. Adrenomedullin expression in human tumor cell lines: its potential role as an autocrine growth factor. J Biol Chem 1996;271:23345-51.
31. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
32. Garayoa M, Martínez A, Lee S, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14:848-62.
33. Giavazzi R, Sennino B, Coltrini D, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003;162:1913-26.
34. Takano S, Tsuboi K, Matsumura A, Nose T. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro-oncol 2003;5:1-7.